{
    "nctId": "NCT04541290",
    "briefTitle": "Tacrolimus as Treatment of Breast Cancer-Related Lymphedema",
    "officialTitle": "Tacrolimus as Treatment of Breast Cancer-Related Lymphedema",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer Lymphedema",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Change in Arm volume from Baseline",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age between 30-65 years\n* Female\n* Lymphedema diagnosis as a result of breast cancer treatment\n* Active Lymphedema (excessive fluid)\n* Significant lymphedema\n* Grade I-II lymphedema\n* Postmenopausal (Absence/lack of menstruation in at least 12 consecutive months) or continuously usage of contraceptive drugs (Spiral, birth-control pills, implant, transdermal patches, vaginal ring or depot injection). Contraceptive drugs must be used throughout the project and at least three weeks subsequent to the ending of the project (last application of the ointment).\n* Clinically good general condition No lymphedema in the opposite arm (normal arm)\n* Understands the purpose og the study and gives written consent to participate\n* Can read and understand the danish language\n\nExclusion Criteria:\n\n* Pregnant, breast-feeding or with wish of pregnancy within the next year\n* Bilateral breast cancer\n* Grade 0, III or IV lymphedema\n* Known allergies for Tacrolimus or and other macrolide\n* Removal of lymph nodes in the opposite armpit\n* Suffers from psychiatric disorders that may affect the participation in the project\n* Reduced kidney or liver function\n* Defect skin-barrier\n* Diagnosed immunodeficiency",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}